See how Worldwide utilized preemptive mitigation and adaptive strategies and a flexible infrastructure to continue trial progress during COVID-19.
Authors:
Michael Murphy, MD, PhD
Chief Medical and Scientific Officer
Paula Penney
Executive Director, Project Management, Alzheimer’s Disease and other Dementias
Natalia Drosopoulou, PhD
Vice President, Project Management, Neuroscience
